A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

BACKGROUND AND AIMS: Myasthenia gravis (MG) is a T-cell dependent antibody-mediated autoimmune disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen, comprising several T and B cell auto-epitopes. We hypothesized that an efficacious drug candidate for antigen-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazaridis, Konstantinos, Fernandez-Santoscoy, Maria, Baltatzidou, Vasiliki, Andersson, Jan-Olof, Christison, Richard, Grünberg, John, Tzartos, Socrates, Löwenadler, Björn, Fribert, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204200/
https://www.ncbi.nlm.nih.gov/pubmed/35720339
http://dx.doi.org/10.3389/fimmu.2022.809106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204200/
https://www.ncbi.nlm.nih.gov/pubmed/35720339
http://dx.doi.org/10.3389/fimmu.2022.809106

Ejemplares similares